Preview

Rational Pharmacotherapy in Cardiology

Advanced search

DIHYDROPYRIDINE CALCIUM ANTAGONISTS. POSITION OF NIFEDIPINE IN MODERN CARDIOLOGY PRACTICE

https://doi.org/10.20996/1819-6446-2011-7-3-356-364

Full Text:

Abstract

Position of nifedipine in modern cardiology practice is highlighted. Nifedipine usage for arterial hypertension therapy , including combined one, stroke prevention, treatment of hypertensive crisis and ischemic heart disease is considered. Advantages of nifedipine innovative formulations are presented. Possible usage of nifedipine in pulmonary hypertension as well as pregnancy is discussed specially.

About the Author

A. A. Garganeeva
Research Institute of Cardiology , Siberian Branch of Russian Academy of Medical Sciences
Russian Federation


References

1. Chazova I.E., Ratova L.G. Three calcium antagonist: the place of each in the treatment of hypertension (ALTERNATIVE study). Sistemnye gipertenzii 2009;4:26-28. Russian (Чазова И.Е., Ратова Л.Г. Три антагониста кальция: место каждого в лечении артериальной гипертензии (исследование АЛЬ-ТЕРНАТИВА). Системные гипертензии 2009;4:26-28).

2. Toyo-Oka T., Nayler W. Third generation calcium entry blockers. Blood Press 1996;5(4):206-8.

3. Furberg C.D., Psaty B.M., Meyer J.V. Nifedipine. Dose–related increase in mortality in patients with coronary heart disease. Ciculation 1995;92:1326–31.

4. Held P.H., Yusuf S., Furberg C.D. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br Med J 1989;299:1187-92.

5. Egstrup K., Andersen P.E. Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol. Am J Cardiol 1993;71:177-83.

6. Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Circulation 1991;84:2598-600.

7. Rafflenbeul W. Nifedipine in acute coronary syndromes: Furberg’s refrain revisited. Eur Heart J 1996;17:1147–52.

8. Tijssen J.G.P., Hugenholtz P.G. Critical appraisal of recent studies on nifedipine and other calcium channel blockers in coronary artery disease and hypertension. Eur Heart J 1996;17:1152–57.

9. Adasheva T.V., Zadionchenko V.S., Timofeeva N.Yu., Danilova N.V. Clinical advantages and pleiotropic effects of calcium antagonists. Aktual'nye voprosy bolezney serdtsa i sosudov 2010; 4:52-58. Russian (Адашева Т.В., Задионченко В.С., Тимофеева Н.Ю., Данилова Н.В. Клинические преимущества и плейотропные эффекты антагонистов кальция. Актуальные вопросы болезней сердца и сосудов 2010; 4:52-58).

10. Martsevich S.Y. Dihydropyridine calcium channel blockers: data of evidence based medicine and recommendations on practical use. Rational Pharmacother Card 2007; 1: 55-59. Russian (Марцевич С.Ю. Антагонисты кальция из группы дигидропиридинов: данные доказательной медицины и практические рекомендации по использованию. Рациональная Фармакотерапия в Кардиологии 2007; 1:55-59).

11. Garganeeva A.A. Calcium channel blockers in patients with high cardiovascular risk. Kardiovaskulyarnaya terapiya i profilaktika 2009; 8(4): 113-120. Russian (Гарганеева А.А. Антагонисты кальция у пациентов с высоким сердечно-сосудистым риском. Кардиоваскулярная терапия и профилактика 2009; 8(4): 113-120).

12. Brown M.J., Palmer C.R., Castaigne A. et al. Principal results from the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Eur Heart J Supplements 2001;3(Suppl B):B20–B26.

13. Brown M., Palmer C., Castaigne A. et al. Morbidity and mortality in patients randomized to double– blind treatment with long–acting calcium channel blocker or diuretic in the Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356(9237):366–72.

14. Lubsen J., Pool-Wilson P.A., Pocock S.J. et al. Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Eur Heart J 1998;19(suppl 1):20-32.

15. Poole-Wilson P.A., Lubsen J., Kirwan B.A. et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004;364:849–57.

16. Lubsen J., Wagner G., Kirwan B.A. et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005;23:641–48.

17. Verdecchia P., Reboldi G., Angeli F. et al. Angiotensin–converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005;46:386–92.

18. Tuomilehto J., Rastenyte D., Birkenhager W.H., Thijs L., Antikainen R., Bulpitt C.J. et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;340:677-84.

19. Celis H., Yodfat Y., Thijs L., Clement D., Cozic J., De Cort P. et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. Fam Pract 1996;13:138-43.

20. Gong L., Zhang W., Zhu Y. et al. Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertens 1996;14(10):1237–45.

21. Whelton P.K., He J., Appel L.J. et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002;288:1882-88.

22. Kita T., Tokashiki M., Kitamura K. Long-Term Therapy with Nifedipine-CR Improves Arterio-Sclerosis Related Markers in Patients with Untreated Essential Hypertension. The Open Hypertension Journal 2008;1:1-6.

23. Luft F.C., Fineberg N.S., Weinberger M.H. et al. Long-term effect of nifedipine and hydrochlorothiazide on blood pressure and sodium homeostasis at varying levels of salt intake in mildly hypertensive patients. Am J Hypertens 1991;4:752–60.

24. National guidelines for diagnosis and treatment of hypertension. Kardivaskulyarnaya terapiya i pro-filaktika 2008; 7 (6) suppl 2:3-32. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертензии. Кардиоваскулярная терапия и профилактика 2008;7(6) приложение 2:3-32).

25. Ruksin V.V., Grishin O.V. Osobennosti neotlozhnykh sostoyaniy, svyazannykh s povysheniem arterial'nogo davleniya, i differentsirovannyy podkhod k okazaniyu skoroy meditsinskoy pomoshchi. Skoraya meditsinskaya pomoshch' 2009;10(2):11–21. Russian (Руксин В.В., Гришин О.В. Особенности неотложных состояний, связанных с повышением артериального давления, и дифференцированный подход к оказанию скорой медицинской помощи. Скорая медицинская помощь 2009;10(2):11–21).

26. Banzet O., Colin J.N., Thibonnier M. et al. Acute antihypertensive effect and pharmacokinetics of a table preparation of nifedipine. Eur J Clin Pharmacol 1983;24:145-50.

27. Donnelly R., Elliott H.L., Meredith P.A. et al. Nifedipine: Individual responses and concentration-effect relationships. Hypertension 1988;12:443-49.

28. Kleinbloesem C.H., van Brummelen P., van de Linde J.A. et al. Nifedipine: kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 1984;35:742-49.

29. Whelton P.K., He J., Appel L.J. et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002;288:1882-88.

30. Anschütz M., Wonnemann M., Schug B. et al. Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. International Journal of Clinical Pharmacology and Therapeutics 2010;48( 2):158-70.

31. Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). Hypertension 2003;42:1206-52.

32. Gauthier B., Trachtman H. Short-acting nifedipine [letter]. Pediatr Nephrol 1997;11(6):786-87.

33. Lubsen J., Wagner G., Kirwan B.A. et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005;23:641–48.

34. Elliott H.L., Meredith P.A. Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the ‘ACTION’ database in patients with angina. Journal of Human Hypertension 2011;25:63–70. Journal of Human Hypertension 2011;65: 63–70.

35. ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease. The ENCORE I study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2002;107:422–28.

36. Lüscher T.F., Pieper M., Tendera M., Vrolix M., Rutsch W. et al. A Randomized Placebo-controlled Study on the Effect of Nifedipine on Coronary Endothelial Function and Plaque Formation in Patients with Coronary Artery Disease: The ENCORE II Study. Eur Heart J 2009;30(13):1590-97.

37. Yui Y., Shinoda E., Kodama K. et al; Japan Multicenter Investigation for Cardiovascular Diseases B (JMIC-B) Study Group. Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy). J Hypertens 2007;25(10):2019-26.

38. Recommendations for a rational pharmacotherapy of patients with cardiovascular diseases. A manual for the system of postgraduate and additional professional education of physicians. Moscow: RSSC; 2009. Russian (Секция Рациональной фармакотерапии ВНОК. Рекомендации по рациональной фармакотерапии больных сердечно-сосудистыми заболеваниями. Учебное пособие для системы послевузовского и дополнительного профессионального образования врачей. М.: ВНОК; 2009).

39. Runikhina N.K., Bart B.Ya., Mikhaylusova M.P. Hypertension in women older than 60 years and the effectiveness of its treatment of the calcium antagonist controlled release of nifedipine. Klinicheskaya Farmakoterapiya 2009;18(3):50-55. Russian (Рунихина Н.К., Барт Б.Я., Михайлусова М.П. Артериальная гипертония у женщин старше 60 лет и эффективность ее лечения антагонистом кальция с контролируемым высвобождением нифедипина. Клиническая Фармакотерапия 2009;18(3):50-55).

40. Statsenko M.E., Piliasova O.V., Paravaeva V.P. Clinical efficacy of the use of prolonged nifedipine in patients with arterial hypertension and chronic obstructive lung disease. Kardiologiia 2008;48(4):34-

41. Russian (Стаценко М.Е., Пилясова О.В., Параваева В.П. Клиническая эффективность применения Кордафлекса РД у больных артериальной гипертензией и хронической обструктивной болезнью легких. Кардиология 2008;4:34-37).

42. Ignatova G.L., Chusova L.M., Gotovtseva G.E., Niskovskaya O.A., Guz' I.O. Experience in applying Cordaflex RD 40 mg in elderly patients with arterial hypertension and chronic obstructive pulmonary disease. Rossiyskiy kardiologicheskiy zhurnal 2007;6(68):51-54.4. Russian (Игнатова Г.Л., Чусова Л.М., Готовцева Г.Е., Нисковская О.А., Гузь И.О. Опыт применения Кордафлекса РД 40 мг у пожилых пациентов, страдающих артериальной гипертензией в сочетании с хронической обструктивной болезнью лёгких. РКЖ 2007;6(68):51-54).

43. Hansson L. et al. Effect of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results in the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.

44. ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007;25:1105-87.

45. Jamerson K. et al. Hydrochlorothiazide for Hypertension in High-Risk Patients. N Engl J Med 2008;359:2417-28.

46. Saito I., Saruta T. ADVANCE-Combi Study Group. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the Adalat CR and Valsartan Cost-Effectiveness Combination (ADVANCE-Combi) study. Hypertens Res 2006;29:789-96.

47. Hasebe N., Kikuchi K. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005;23:445–53.

48. Epstein M. Recent landmark clinical trials: how do they modify the therapeutic paradigm?” Am J Hypertens 2002;15:82S–84S.

49. Galie` N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493–537.

50. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76–81.

51. Sitbon O., Humbert M., Jais X., Ioos V., Hamid A.M., Provencher S., Garcia G., Parent F., Herve P., Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105–11.

52. Abalos E., Duley L., Steyn D.W., Henderson-Smart D.J. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2001;(2):CD002252 .

53. Caruso A., Ferrazzani S., De Carolis S. et al. The use of nifedipine as first-line hypotensive therapy in gestational hypertension. Minerva Ginecol 1994;46(5):279-84.

54. Brown M.A., Buddle M.L., Farrell T. et al. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am J Obstet Gynecol 2002;187(4):1046-50.

55. Bakris G. The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states. J Am Soc Nephrol 1991; 2(Suppl):21-9.

56. Manninen A. Nifedipin reduses thromboxane A2 production by platelets without changing aggregation in hypertensive pregnancy. Pharmacol Toxcol 1996:78(6):387-91.

57. Runikhina N.K., Bart B.Ya., Tkacheva O.N. Modern antihypertensive therapy in pregnancy: efficacy and safety of long-acting nifedipine (literature review and own data). Farmateka 2008; 14:49-56. Russian (Рунихина Н.К., Барт Б.Я., Ткачева О.Н. Современная антигипертензивная терапия у беременных: эффективность и безопасность пролонгированных форм нифедипина (Обзор литературы и собственные данные). Фарматека 2008; 14:49-56).

58. Mortimer P.S. Implications of the lymphatic system in CVI-associated edema. Angiology 2000; 51:3–7.

59. Weir M.R. Incidence of Pedal Edema Formation With Dihydropyridine Calcium Channel Blockers: Issues and Practical Significance. J Clin Hypertens 2003;5:330–5.

60. Makani H., Bangalore S., Romero J. et al. Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema. The American Journal of Medicine 2011;124:128-35.


For citation:


Garganeeva A.A. DIHYDROPYRIDINE CALCIUM ANTAGONISTS. POSITION OF NIFEDIPINE IN MODERN CARDIOLOGY PRACTICE. Rational Pharmacotherapy in Cardiology. 2011;7(3):356-364. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-3-356-364

Views: 860


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)